Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus.
about
Genetic, hormonal and metabolic aspects of PCOS: an updateTau clearance mechanisms and their possible role in the pathogenesis of Alzheimer diseaseMaintenance of synaptic stability requires calcium-independent phospholipase A₂ activityThe Dynamics and Turnover of Tau Aggregates in Cultured Cells: INSIGHTS INTO THERAPIES FOR TAUOPATHIES.Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.Combinatorial strategies for targeting protein families: application to the proteases.A caspase cleaved form of tau is preferentially degraded through the autophagy pathway.Double vision: pigment genes do more than just colorCholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brainIn silico pharmacology for drug discovery: applications to targets and beyondTFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits.Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice.Allopregnanolone treatment delays cholesterol accumulation and reduces autophagic/lysosomal dysfunction and inflammation in Npc1-/- mouse brain.A multienzyme network functions in intestinal protein digestion by a platyhelminth parasite.Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.Blockade of NR2A-containing NMDA receptors induces Tau phosphorylation in rat hippocampal slices.Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy.Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis--an approach for slowing Alzheimer disease?Association between cathepsin D polymorphism and Alzheimer's disease in a Chinese Han population.Hybrid 2D/3D-quantitative structure-activity relationship and modeling studies perspectives of pepstatin A analogs as cathepsin D inhibitors.Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease.A novel approach for characterization of cathepsin D protease and its effect on tau and β-amyloid proteins.
P2860
Q26740034-5393D88E-6992-425E-8E1C-275994CFA77EQ26995276-D41A6E08-0436-4A9A-889F-B03887FF408FQ27027705-9832DBE2-12E6-48FC-9D3A-4AF822EECB19Q30780758-1789EC10-1CBA-460F-A2DA-FABDBF76619FQ33237201-EA2207F6-AACA-43D1-9411-60488A490233Q33288760-0CAD924F-4386-407F-8D71-36B1C965EA6FQ33991036-4194FAE3-DE74-4E52-8DBE-B3C5563E6F72Q35577803-1F651E19-B28F-4598-9E7B-C56C084737BDQ35963203-825E896F-1315-4D8E-8A3C-53A056688799Q35995265-45BCD6AB-8DD8-4469-9C25-5F67163D55D7Q36925612-0713FE22-3054-4D80-8CA7-8B97850BA792Q37117419-39F3D837-BC0C-4574-A3F2-3E0605674CB1Q37179554-E0308BC4-3EFA-4E55-AEBD-59064D30FFD5Q38969130-AF016B40-1399-4555-8764-7DC005706097Q38983187-3EF77E30-A724-462F-A73D-C66B997724C1Q40700702-3DB954D5-ACFB-49D7-BD99-648624637A63Q41854251-D3CE020C-CAF3-47A8-AE5C-75419836F097Q41915822-430E2C7F-DBC2-4B8C-9255-61B91F3E4BF1Q44947294-B44661A1-ECDD-445E-826B-55421126F0A5Q46840528-D520F81C-E279-41DB-8A2A-655F7152F256Q48421283-04C426DA-6225-4960-BE75-B4E31ABCA5EAQ50313086-545B15E0-675F-49CD-BF36-3071D1B4A952
P2860
Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Novel cathepsin D inhibitors b ...... tau fragments in hippocampus.
@en
type
label
Novel cathepsin D inhibitors b ...... tau fragments in hippocampus.
@en
prefLabel
Novel cathepsin D inhibitors b ...... tau fragments in hippocampus.
@en
P2093
P2860
P1476
Novel cathepsin D inhibitors b ...... d tau fragments in hippocampus
@en
P2093
A G Skillman
J A Ellman
P2860
P304
P356
10.1046/J.1471-4159.2000.0741469.X
P407
P50
P577
2000-04-01T00:00:00Z